I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... during the coming 2022/23 flu season in the northern hemisphere.

Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

BioNTech (NASDAQ:BNTX) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

Catching the virus that causes COVID-19 or getting a COVID-19 vaccination gives you protection, also called immunity, from the virus. But over time, that protection seems to ...

The FDA issued Emergency Use Authorization for the Pfizer-BioNTech vaccine on Dec. 11, 2020, and for the Moderna vaccine on Dec. 18, 2020 for those 18 and older. Novavax was approved June 7, 2022 ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

As a summer wave of Covid-19 continues to hit the United States, the US Food and Drug Administration on Thursday signed off on updated Covid-19 vaccines from Moderna and Pfizer/BioNTech.

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...